Elsulfavirine
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Elsulfavirine
- DrugBank Accession Number
- DB14929
- Background
Elsulfavirine is under investigation in clinical trial NCT03706898 (Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 629.28
Monoisotopic: 626.943338 - Chemical Formula
- C24H17BrCl2FN3O5S
- Synonyms
- Elsulfavirine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as bromodiphenyl ethers. These are compounds that contain two benzene groups linked to each other via an ether bond, and where at least one ring is substituted with a bromo group.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylethers
- Direct Parent
- Bromodiphenyl ethers
- Alternative Parents
- Diarylethers / Phenylacetamides / Benzenesulfonamides / Anilides / Benzenesulfonyl compounds / Phenoxy compounds / Phenol ethers / Benzonitriles / N-arylamides / Bromobenzenes show 15 more
- Substituents
- Aminosulfonyl compound / Anilide / Aromatic homomonocyclic compound / Aryl bromide / Aryl chloride / Aryl fluoride / Aryl halide / Benzenesulfonamide / Benzenesulfonyl group / Benzonitrile show 32 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- ZC4CGO0RUG
- CAS number
- 868046-19-9
- InChI Key
- ULTDEARCBRNRGR-UHFFFAOYSA-N
- InChI
- InChI=1S/C24H17BrCl2FN3O5S/c1-2-21(32)31-37(34,35)17-4-6-20(19(27)11-17)30-22(33)9-14-3-5-18(25)24(23(14)28)36-16-8-13(12-29)7-15(26)10-16/h3-8,10-11H,2,9H2,1H3,(H,30,33)(H,31,32)
- IUPAC Name
- N-(4-{2-[4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]acetamido}-3-chlorobenzenesulfonyl)propanamide
- SMILES
- CCC(=O)NS(=O)(=O)C1=CC(Cl)=C(NC(=O)CC2=CC=C(Br)C(OC3=CC(=CC(Cl)=C3)C#N)=C2F)C=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 9702305
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 2, 3 Completed Treatment Human Immunodeficiency Virus Type 1 (HIV-1) Infection 1 1 Completed Basic Science Human Immunodeficiency Virus Type 1 (HIV-1) Infection 1 1 Completed Treatment Coronavirus Disease 2019 (COVID‑19) / Human Immunodeficiency Virus Type 1 (HIV-1) Infection 1 1 Completed Treatment Hepatic Impairment / Human Immunodeficiency Virus Type 1 (HIV-1) Infection 1 1 Completed Treatment Human Immunodeficiency Virus (HIV) Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000601 mg/mL ALOGPS logP 5.3 ALOGPS logP 5.82 Chemaxon logS -6 ALOGPS pKa (Strongest Acidic) 3.24 Chemaxon pKa (Strongest Basic) -3.8 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 125.36 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 141.4 m3·mol-1 Chemaxon Polarizability 54.83 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at May 20, 2019 14:35 / Updated at February 21, 2021 18:55